

problem is shown, which we anticipate to be there. There is no question about that.

Senator NELSON. You anticipate that there will be strong evidence of abuse?

Dr. CROUT. Yes; for amphetamines. I think for the class as a whole, you will find when the facts are all in, that a distinction can be drawn in the abuse area between those drugs on schedule II and those in III and IV.

Senator NELSON. As you probably know, Dr. Henderson, from Ottawa, Canada, who was chairman in Canada of the committee that recommended removal of the indication of amphetamines for the treatment of obesity appeared before this subcommittee. He has now concluded that it should apply to the congeners, also, I believe he said, except for fenfluramine.

I do not know whether he said that.

Dr. CROUT. We will be interested in what Canada does. We are in touch with Canada on this.

Senator NELSON. I think the record shows that Dr. Edwards, when he was Commissioner, said that most studies of these preparations showed efficacy for short periods. The panel suggested that long-term studies should be conducted. This was in 1970.

Have long-term studies been initiated on weight reduction, or have producers of the drugs been requested to produce studies?

Dr. Edwards suggested long-term studies of the effects of these drugs 6 years ago.

Dr. CROUT. I am not familiar with that request.

Mr. MERRILL. There are two parts of the question, I think, Mr. Chairman.

One is whether or not there should be data from well-controlled studies.

Senator NELSON. Pardon?

Mr. MERRILL. I think there are two parts of the question. One is whether or not there should be data from adequate and well-controlled studies, covering long periods, versus very short periods.

Such data covering short periods of use were submitted and evaluated.

Senator NELSON. Such studies were what?

Mr. MERRILL. Such studies were submitted to the agency.

Senator NELSON. Long-term?

Mr. MERRILL. No; I think it is true the manufacturers have not done that so far as we know. I think they may now be doing it, but to span the length of a lifetime—

Senator NELSON. I am not even talking about lifetime.

I am talking of 1 year, 2 years.

Dr. CROUT. Why is that different from 5 years, 10 years, 20 years?

Senator NELSON. Well, if something is good for only 20 seconds, you ought to remove it from the market.

If you are talking about an impact of a half-pound a week, treated for 12 or 13 weeks and then the patient ends up in the same position 12 months later—

Dr. CROUT. How do you know that he ends up in the same position 12 months later?

Senator NELSON. We do not know.